Engy Habashy, MD, discusses key takeaways from the 2025 AUA GSM guideline, including the role of androgens and hormonal therapies in managing genitourinary syndrome of menopause.
|Articles|February 1, 2004
Good and bad news: ED patients often don't return
Author(s)Louise Gagnon
Quebec City, Quebec--The good news is that most patients being treated for erectile dysfunction report that their treatment is working. The bad news is that a significant percentage of these same patients are often lost to follow-up for that very reason, according to a study by urologists from McGill University.
Advertisement
Advertisement
Related to this article
Chad R. Ritch, MD, MBA, FACS, discusses how PSMA-PET informs staging, treatment planning, recurrence workup, and the interpretation of equivocal findings.
Michael S. Cookson, MD, MMHC, FACS, discusses how Anktiva’s expanded FDA approval may broaden bladder-preserving treatment options for BCG-unresponsive papillary-only NMIBC.
Jeffrey M. Spier, MD, discusses how fatigue may impact patient quality-of-life and when dose reduction may be an appropriate treatment strategy.
This approval expands the perioperative use of pembrolizumab plus enfortumab vedotin to all patients with MIBC, regardless of cisplatin eligibility.
Take a look through some of the notable data presentations at this year's ESMO Congress.
The investigational HIF-2α inhibitor casdatifan demonstrated antitumor activity as monotherapy and in combination regimens across the ARC-20 platform study.
The agency issued a PDUFA target action date of June 14, 2027.
Advertisement
Advertisement
Trending on Urology Times
1
How PSMA-PET shapes staging and recurrence workup in prostate cancer
2
European Commission approves perioperative pembrolizumab plus enfortumab vedotin for MIBC
3
Engy Habashy, MD, on the role of androgens in GSM management
4
ESMO 2026: Key presentations across genitourinary oncology
5